Clinical Trial Search

Phase 2 N=117 Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

Metastatic Colorectal Adenocarcinoma

Primary: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B — 39.3 Percentage of Participants

Seagen Inc. Results Apr 2023 20.1% serious AE View details

Phase 2 N=34 A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

Primary: 24-Week Progression-Free Survival Rate (PFSR) — 59.8; 16.7 percentage of participants

Takeda Results Apr 2023 26.5% serious AE View details

Phase 2 N=24 Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors

Solid Tumors

Primary: Number of Participants With Overall Response Rate (ORR) — 2; 6 Participants

M.D. Anderson Cancer Center Results Apr 2023 45.8% serious AE View details

Phase 2 N=29 BN Brachyury and Radiation in Chordoma

Chordoma

Primary: Objective Response Rate (ORR) — 7.7 percentage of subjects with OR

Bavarian Nordic Results Apr 2023 27.6% serious AE View details

Phase 2 N=19 Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis

Psoriasis

Primary: Subjects With >=75% Reduction in Baseline Psoriasis Area and Severity Index (PASI) (Efficacy) — 3; 1 Participants — p=0.43

Syntrix Biosystems, Inc. Results Apr 2023 5.3% serious AE View details

Phase 2 N=10 Transplanting Hepatitis C Lungs Into Negative Lung Recipients

Lung Diseases

Primary: Subject Sustained Virologic Response (SVR-12) at 12-weeks Post-treatment — 10 Participants

University of Pennsylvania Results Apr 2023 0.0% serious AE View details

Phase 2 N=43 Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection

HIV · Human Immunodeficiency Virus

Primary: Time to Virologic Failure After Initiating PRO 140 Monotherapy. — 70.71 days — p=<0.0001

CytoDyn, Inc. Results Apr 2023 2.3% serious AE View details

Phase 2 N=20 Patient-Controlled Anxiolysis With Dexmedetomidine (PCA-DEX) for Burn-care Dressing Changes

Anxiety · Burns

Primary: Number of Participants Successfully Completing the Pilot Trial Without Adverse Effects — 16 Participants

Ohio State University Results Apr 2023 0.0% serious AE View details

Phase 2 N=195 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)

Ulcerative Colitis

Primary: Percentage of Participants With Clinical Remission at Week 8 — 5; 4; 5; 11 Participants

Genentech, Inc. Results Apr 2023 2.6% serious AE View details

Phase 2 N=75 Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis

Nonalcoholic Steatohepatitis · Nonalcoholic Fatty Liver Disease

Primary: Percent Change From Baseline (CFB) in Percent (%) Liver Fat as Assessed Via Magnetic Resonance Imaging Using Proton Density Fat Fraction Acquisition (MRI-PDFF) at Week 6…

Pfizer Results Apr 2023 0.0% serious AE View details

Phase 2 N=71 Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)

Overt Hepatic Encephalopathy

Primary: Time to Overt Hepatic Encephalopathy (OHE) Resolution Determined Using the Hepatic Encephalopathy Grading Instrument (HEGI), Defined as HEGI Score < 2 — 36.1; 21.1…

Bausch Health Americas, Inc. Results Apr 2023 34.7% serious AE View details